150 related articles for article (PubMed ID: 36969886)
21. [P4HA2 promotes occurrence and progression of liver cancer by regulating the PI3K/Akt/mTOR signaling pathway].
Shang L; Jiang W; Zhang J; Wu W
Nan Fang Yi Ke Da Xue Xue Bao; 2022 May; 42(5):665-672. PubMed ID: 35673909
[TBL] [Abstract][Full Text] [Related]
22. Preclinical efficacy of a novel dual PI3K/mTOR inhibitor, CMG002, alone and in combination with sorafenib in hepatocellular carcinoma.
Kim MN; Lee SM; Kim JS; Hwang SG
Cancer Chemother Pharmacol; 2019 Oct; 84(4):809-817. PubMed ID: 31385002
[TBL] [Abstract][Full Text] [Related]
23. Elevated PDK1 Expression Drives PI3K/AKT/MTOR Signaling Promotes Radiation-Resistant and Dedifferentiated Phenotype of Hepatocellular Carcinoma.
Bamodu OA; Chang HL; Ong JR; Lee WH; Yeh CT; Tsai JT
Cells; 2020 Mar; 9(3):. PubMed ID: 32197467
[TBL] [Abstract][Full Text] [Related]
24. Correlation of LAGE3 with unfavorable prognosis and promoting tumor development in HCC via PI3K/AKT/mTOR and Ras/RAF/MAPK pathways.
Li Y; Xiong H
BMC Cancer; 2022 Mar; 22(1):298. PubMed ID: 35313850
[TBL] [Abstract][Full Text] [Related]
25. Overexpression of brachyury contributes to tumor metastasis by inducing epithelial-mesenchymal transition in hepatocellular carcinoma.
Du R; Wu S; Lv X; Fang H; Wu S; Kang J
J Exp Clin Cancer Res; 2014 Dec; 33(1):105. PubMed ID: 25499255
[TBL] [Abstract][Full Text] [Related]
26. DNA primase subunit 1 deteriorated progression of hepatocellular carcinoma by activating AKT/mTOR signaling and UBE2C-mediated P53 ubiquitination.
Zhu M; Wu M; Bian S; Song Q; Xiao M; Huang H; You L; Zhang J; Zhang J; Cheng C; Ni W; Zheng W
Cell Biosci; 2021 Feb; 11(1):42. PubMed ID: 33622397
[TBL] [Abstract][Full Text] [Related]
27. miR-300 regulates the epithelial-mesenchymal transition and invasion of hepatocellular carcinoma by targeting the FAK/PI3K/AKT signaling pathway.
Wang R; Yu Z; Chen F; Xu H; Shen S; Chen W; Chen L; Su Q; Zhang L; Bi J; Zeng W; Li W; Huang X; Wang Q
Biomed Pharmacother; 2018 Jul; 103():1632-1642. PubMed ID: 29864952
[TBL] [Abstract][Full Text] [Related]
28. Sphingosine 1-phosphate receptor 2 promotes the onset and progression of non-alcoholic fatty liver disease-related hepatocellular carcinoma through the PI3K/AKT/mTOR pathway.
Wang G; Zhang X; Zhou Z; Song C; Jin W; Zhang H; Wu W; Yi Y; Cui H; Zhang P; Liu X; Xu W; Shen X; Shen W; Wang X
Discov Oncol; 2023 Jan; 14(1):4. PubMed ID: 36631680
[TBL] [Abstract][Full Text] [Related]
29. SOX18 Affects Cell Viability, Migration, Invasiveness, and Apoptosis in Hepatocellular Carcinoma (HCC) Cells by Participating in Epithelial-to-Mesenchymal Transition (EMT) Progression and Adenosine Monophosphate Activated Protein Kinase (AMPK)/Mammalian Target of Rapamycin (mTOR).
Sun Y; Lei B; Huang Q
Med Sci Monit; 2019 Aug; 25():6244-6254. PubMed ID: 31427562
[TBL] [Abstract][Full Text] [Related]
30. miR-34a and miR-125a-5p inhibit proliferation and metastasis but induce apoptosis in hepatocellular carcinoma cells via repressing the MACC1-mediated PI3K/AKT/mTOR pathway.
Zhang YM; Wu QM; Chang LY; Liu JC
Neoplasma; 2020 Sep; 67(5):1042-1053. PubMed ID: 32484698
[TBL] [Abstract][Full Text] [Related]
31. An epithelial-mesenchymal transition-related 5-gene signature predicting the prognosis of hepatocellular carcinoma patients.
Zhu G; Xia H; Tang Q; Bi F
Cancer Cell Int; 2021 Mar; 21(1):166. PubMed ID: 33712026
[TBL] [Abstract][Full Text] [Related]
32. Activation of PI3K/AKT is involved in TINAG-mediated promotion of proliferation, invasion and migration of hepatocellular carcinoma.
Zhang MH; Niu H; Li Z; Huo RT; Wang JM; Liu J
Cancer Biomark; 2018; 23(1):33-43. PubMed ID: 29991125
[TBL] [Abstract][Full Text] [Related]
33. p53 haploinsufficiency and increased mTOR signalling define a subset of aggressive hepatocellular carcinoma.
Luo YD; Fang L; Yu HQ; Zhang J; Lin XT; Liu XY; Wu D; Li GX; Huang D; Zhang YJ; Chen S; Jiang Y; Shuai L; He Y; Zhang LD; Bie P; Xie CM
J Hepatol; 2021 Jan; 74(1):96-108. PubMed ID: 32738450
[TBL] [Abstract][Full Text] [Related]
34. PRMT9 promotes hepatocellular carcinoma invasion and metastasis via activating PI3K/Akt/GSK-3β/Snail signaling.
Jiang H; Zhou Z; Jin S; Xu K; Zhang H; Xu J; Sun Q; Wang J; Xu J
Cancer Sci; 2018 May; 109(5):1414-1427. PubMed ID: 29603830
[TBL] [Abstract][Full Text] [Related]
35. Novel lncRNA SFTA1P Promotes Tumor Growth by Down-Regulating miR-4766-5p via PI3K/AKT/mTOR Signaling Pathway in Hepatocellular Carcinoma.
Huang G; Yang Y; Lv M; Huang T; Zhan X; Kang W; Hou J
Onco Targets Ther; 2020; 13():9759-9770. PubMed ID: 33061455
[TBL] [Abstract][Full Text] [Related]
36. Effect of nicastrin on hepatocellular carcinoma proliferation and apoptosis through PI3K/AKT signalling pathway modulation.
Wang X; Wang X; Xu Y; Yan M; Li W; Chen J; Chen T
Cancer Cell Int; 2020; 20():91. PubMed ID: 32226312
[TBL] [Abstract][Full Text] [Related]
37. LncRNA DARS-AS1 aggravates the growth and metastasis of hepatocellular carcinoma via regulating the miR-3200-5p-Cytoskeleton associated protein 2 (CKAP2) axis.
Feng Y; Wei G; Zhang L; Zhou H; Wang W; Guo P; Cheng C; Ji L; Cai Q; Feng Y; Tu H
Bioengineered; 2021 Dec; 12(1):8217-8232. PubMed ID: 34596006
[TBL] [Abstract][Full Text] [Related]
38. ARHGAP9 inhibits colorectal cancer cell proliferation, invasion and EMT via targeting PI3K/AKT/mTOR signaling pathway.
Sun J; Zhao X; Jiang H; Yang T; Li D; Yang X; Jia A; Ma Y; Qian Z
Tissue Cell; 2022 Aug; 77():101817. PubMed ID: 35679685
[TBL] [Abstract][Full Text] [Related]
39. EEF1A2 inactivates p53 by way of PI3K/AKT/mTOR-dependent stabilization of MDM4 in hepatocellular carcinoma.
Pellegrino R; Calvisi DF; Neumann O; Kolluru V; Wesely J; Chen X; Wang C; Wuestefeld T; Ladu S; Elgohary N; Bermejo JL; Radlwimmer B; Zörnig M; Zender L; Dombrowski F; Evert M; Schirmacher P; Longerich T
Hepatology; 2014 May; 59(5):1886-99. PubMed ID: 24285179
[TBL] [Abstract][Full Text] [Related]
40. MST4 negatively regulates the EMT, invasion and metastasis of HCC cells by inactivating PI3K/AKT/Snail1 axis.
Dian MJ; Li J; Zhang XL; Li ZJ; Zhou Y; Zhou W; Zhong QL; Pang WQ; Lin XL; Liu T; Liu YA; Li YL; Han LX; Zhao WT; Jia JS; Xiao SJ; Xiao D; Xia JW; Hao WC
J Cancer; 2021; 12(15):4463-4477. PubMed ID: 34149910
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
